Wall Street brokerages expect that RTI Surgical Inc (NASDAQ:RTIX) will report sales of $70.16 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for RTI Surgical’s earnings, with the lowest sales estimate coming in at $69.49 million and the highest estimate coming in at $70.82 million. RTI Surgical reported sales of $71.35 million in the same quarter last year, which indicates a negative year over year growth rate of 1.7%. The firm is expected to announce its next quarterly earnings results before the market opens on Thursday, March 1st.
On average, analysts expect that RTI Surgical will report full year sales of $70.16 million for the current year, with estimates ranging from $278.40 million to $279.56 million. For the next fiscal year, analysts anticipate that the firm will post sales of $282.10 million per share, with estimates ranging from $281.94 million to $282.26 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that that provide coverage for RTI Surgical.
Separately, BidaskClub cut shares of RTI Surgical from a “hold” rating to a “sell” rating in a report on Tuesday, December 5th.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Prudential Financial Inc. purchased a new position in shares of RTI Surgical during the third quarter valued at approximately $111,000. SG Americas Securities LLC purchased a new position in shares of RTI Surgical during the fourth quarter valued at approximately $113,000. Citadel Advisors LLC raised its holdings in shares of RTI Surgical by 85.7% during the third quarter. Citadel Advisors LLC now owns 26,786 shares of the medical equipment provider’s stock valued at $122,000 after purchasing an additional 12,361 shares during the last quarter. Citigroup Inc. increased its holdings in RTI Surgical by 2,850.1% during the second quarter. Citigroup Inc. now owns 21,152 shares of the medical equipment provider’s stock valued at $124,000 after buying an additional 20,435 shares during the last quarter. Finally, Bronfman E.L. Rothschild L.P. purchased a new stake in RTI Surgical during the fourth quarter valued at approximately $137,000. 59.83% of the stock is owned by hedge funds and other institutional investors.
Shares of RTI Surgical (RTIX) remained flat at $$4.50 during midday trading on Monday. The company had a trading volume of 66,300 shares, compared to its average volume of 129,296. The stock has a market cap of $273.75, a P/E ratio of -64.29, a P/E/G ratio of 2.00 and a beta of 1.71. RTI Surgical has a 1 year low of $3.42 and a 1 year high of $6.00. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.34 and a quick ratio of 1.21.
WARNING: This piece of content was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/22/analysts-anticipate-rti-surgical-inc-rtix-will-announce-quarterly-sales-of-70-16-million.html.
About RTI Surgical
RTI Surgical, Inc is engaged in producing orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues. The Company uses natural tissues, metals and synthetics process to produce its products. The Company’s business primarily consists of six categories, such as spine, sports medicine, ortho fixation, bone graft substitutes and general orthopedic (BGS and general orthopedic), dental and surgical specialties.
Get a free copy of the Zacks research report on RTI Surgical (RTIX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for RTI Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RTI Surgical and related companies with MarketBeat.com's FREE daily email newsletter.